Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noah Federman

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
NPJ Precision Oncology|September 6, 2022
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibitionNoah Federman
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
Achieving durable response with the TRK inhibitor larotrectinib, and possible discontinuation of therapy in pediatric NTRK gene fusion-positive solid tumorsNoah Federman, Camille Hamilton
Sarcoma|May 9, 2012
Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapiesBryan Mitton, Noah Federman
Expert Review of Clinical Pharmacology|August 31, 2019
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerNoah Federman, Ray McDermott
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2007
PET/CT in evaluating pediatric malignancies: a clinician's perspectiveNoah Federman, Stephen A Feig
Medgenmed : Medscape General Medicine|December 22, 2005
Topics in pediatric leukemia--Fanconi's anemia: new insightsNoah Federman, Kathleen M Sakamoto
Pediatric Research|February 2, 2010
Targeting liposomes toward novel pediatric anticancer therapeuticsNoah Federman, Christopher T Denny
Molecular Genetics and Metabolism|August 30, 2005
The genetic basis of bone marrow failure syndromes in childrenNoah Federman, Kathleen M Sakamoto
Expert Review of Anticancer Therapy|October 27, 2012
Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomasBartosz Chmielowski, Noah Federman, William D Tap
Pediatric Research|November 24, 2015
Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccinesTheodore S Nowicki, Jennifer L Anderson, Noah Federman
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
NPJ Precision Oncology|September 6, 2022
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibitionNoah Federman
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
Achieving durable response with the TRK inhibitor larotrectinib, and possible discontinuation of therapy in pediatric NTRK gene fusion-positive solid tumorsNoah Federman, Camille Hamilton
Sarcoma|May 9, 2012
Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapiesBryan Mitton, Noah Federman
Expert Review of Clinical Pharmacology|August 31, 2019
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerNoah Federman, Ray McDermott
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2007
PET/CT in evaluating pediatric malignancies: a clinician's perspectiveNoah Federman, Stephen A Feig
Medgenmed : Medscape General Medicine|December 22, 2005
Topics in pediatric leukemia--Fanconi's anemia: new insightsNoah Federman, Kathleen M Sakamoto
Pediatric Research|February 2, 2010
Targeting liposomes toward novel pediatric anticancer therapeuticsNoah Federman, Christopher T Denny
Molecular Genetics and Metabolism|August 30, 2005
The genetic basis of bone marrow failure syndromes in childrenNoah Federman, Kathleen M Sakamoto
Expert Review of Anticancer Therapy|October 27, 2012
Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomasBartosz Chmielowski, Noah Federman, William D Tap
Pediatric Research|November 24, 2015
Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccinesTheodore S Nowicki, Jennifer L Anderson, Noah Federman
Pageof 12